• SELECT SITE CURRENCY
Select a currency for use throughout the site
What are European Physician and Payer Expectations for the Uptake of Emerging Oral Immunomodulators in Rheumatoid Arthritis?
Decision Resources, Inc, December 2011, Pages: 142
The moderate-to-severe RA population is a lucrative indication for immune-targeted agents owing to its high prevalence and size of the patient population refractory to cheap and generic conventional therapies.
However, the barriers to entry are high given the number of effective biologic therapies already marketed; these include five tumor necrosis factor-alpha (TNF-a) inhibitors, Bristol-Myers Squibb/Ono Pharmaceutical’s selective costimulation modulator Orencia, Roche’s MabThera (Roche/Biogen Idec Chugai/Zenyaku Kogyo’s B-cell inhibitor Rituxan), and the more recently-launched interleukin-6 (IL-6) inhibitor Actemra/RoActemra from Roche/Chugai.
However, two oral agents—Pfizer/Takeda’s tofacitinib (CP-690550) and AstraZeneca’s fostamatinib disodium (R-788)—are set to launch in Europe over the next four years and aim to compete with the TNF-a inhibitors. The introduction of novel formulations for three already-marketed biologics (including subcutaneous formulations of Orencia and RoActemra) has the potential to further fragment the moderate-to-severe RA market.
Executive Summary Slides
Commercial Context Slides
Overview and Analysis of Reimbursement in the EU5 Slides
Analysis of Survey Results Slides
About the Author Slide
For Further Information Slide